FDA approved drugs:
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Nexavar
18
49
|
SORAFENIB TOSYLATE |
Bayer/Onyx |
December 2005 |
Disease/s that Drug Treats:Renal Cell Carcinoma
Indications and Usage:
18
NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:
16
1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1
Mechanism of Action:
18
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.
|
Drugs for Differentiated Thyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 145)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Lenvatinib |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
417716-92-8 |
|
|
Synonyms:
4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
E7080
|
|
|
| 2 |
|
Protein Kinase Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 3 |
|
Sorafenib |
Approved, Investigational |
Phase 3,Phase 2 |
|
284461-73-0 |
216239
406563
|
|
Synonyms:
284461-73-0
4-(4-((((4-chloro-3-(Trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-(3-(4-chloro-3-Trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 439006
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY43-9006
BAY-43-9006
BAY-54-9085
Bio-0100
BRD-K23984367-001-01-8
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
D08524
|
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(Trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
nchembio.117-comp17
Nexavar
NSC-724772
NSC747971
sorafenib
Sorafenib
Sorafenib (INN)
Sorafenib [INN]
Sorafenib N-oxide
Sorafenib tosylate
sorafenibum
Sorafenibum
STK627350
UNII-9ZOQ3TZI87
ZINC01493878
|
|
| 4 |
|
Iodine |
Approved, Investigational |
Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
7553-56-2 |
807
|
|
Synonyms:
diiodine
I2
Iode
Iodine-molecule
Iodio
Iodum
|
Jod
Jood
molecular iodine
Molecular iodine
Tincture iodine
|
|
| 5 |
|
Nicotinamide |
Approved, Investigational |
Phase 3,Phase 2 |
|
98-92-0 |
936
|
|
Synonyms:
.beta.-Pyridinecarboxamide
11032-50-1
123574-63-0
1yc5
3 Pyridinecarboxamide
37321-14-5
3-Carbamoylpyridine
3-Pyridinecarboxamide
3-Pyridinecarboxylic acid amide
47865U_SUPELCO
55600-01-6
63748-44-7
72340_FLUKA
72340_SIGMA
72347_FLUKA
78731-47-2
98-92-0
A186B02E-6C70-4E54-9739-79398D439AAA
AC1L1ACZ
AC1Q4ZFV
AC-907/25014114
Acid amide
AI3-02906
Amid kyseliny nikotinove
Amid kyseliny nikotinove [Czech]
Amide PP
Aminicotin
Amixicotyn
Amnicotin
Astra brand OF niacinamide
Astra Brand of Niacinamide
Austrovit PP
b 3, Vitamin
B 3, Vitamin
b3, Vitamin
B3, Vitamin
BB_NC-2290
Benicot
beta-Pyridinecarboxamide
bmse000281
b-Pyridinecarboxamide
C00153
C6H6N2O
CCRIS 1901
CHEBI:17154
CHEMBL1140
CID936
CPD000058212
D00036
D009536
DB02701
DEA No. 1405
Delonin amide
Dipegyl
Dipigyl
EINECS 202-713-4
EINECS 234-265-0
Endobion
Enduramide
Factor pp
Factor PP
Hansamid
HMS2052M21
HMS2090B05
HMS2093H03
HSDB 1237
I02-1741
I02-2250
InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9
Inovitan PP
Jenapharm brand OF niacinamide
Jenapharm Brand of Niacinamide
Jenapharm, Nicotinsaureamid
Jenapharm, nicotinsäureamid
LS-2051
m-(Aminocarbonyl)pyridine
Mediatric
Merck brand OF niacinamide
Merck Brand of Niacinamide
MLS000069714
MolMap_000061
MolPort-001-783-876
N0078
N0636_SIGMA
N2142_SIGMA
N3376_SIGMA
N5535_SIAL
NAM
Nandervit-N
NCGC00093354-03
NCGC00093354-04
nchembio.154-comp4
nchembio.73-comp6
Niacevit
Niacin
niacin - Vitamin B3
niacinamide
Niacinamide
Niacinamide (USP)
Niacinamide [USAN]
|
Niacinamide astra brand
Niacinamide Astra Brand
Niacinamide jenapharm brand
Niacinamide Jenapharm Brand
Niacinamide merck brand
Niacinamide Merck Brand
Niacinamide pharmagenix brand
Niacinamide Pharmagenix Brand
Niacinamide, Nicotinic acid amide, Nicotinamide
Niacotinamide
Niamide
Niavit PP
Nicamide
Nicamina
Nicamindon
Nicasir
Nicobion
Nicofort
Nicogen
Nicomidol
Nicosan 2
Nicosylamide
Nicota
Nicotamide
Nicotilamide
Nicotililamido
Nicotinamid
Nicotinamida
Nicotinamida [INN-Spanish]
nicotinamide
Nicotinamide
Nicotinamide (JP15/INN)
Nicotinamide (Niacinamide)
Nicotinamide, niacin, vitamin B3
Nicotinamide-carbonyl-14C
Nicotinamidum
Nicotinamidum [INN-Latin]
Nicotinate amide
Nicotine acid amide
Nicotine amide
Nicotinic acid amide
Nicotinic amide
Nicotinsaeureamid
Nicotinsaureamid
Nicotinsaureamid [German]
Nicotinsaureamid Jenapharm
Nicotinsäureamid jenapharm
Nicotol
Nicotylamide
Nicotylamidum
Nicovel
Nicovit
Nicovitina
Nicovitol
Nicozymin
Nictoamide
Nikasan
Nikazan
niko-Tamin
Niko-tamin
Nikotinamid
Nikotinsaeureamid
Nikotinsaeureamid [German]
Niocinamide
Niozymin
NSC 13128
NSC13128
NSC27452
Papulex
Pelmin
Pelmine
Pelonin amide
Pharmagenix brand OF niacinamide
Pharmagenix Brand of Niacinamide
PP-Faktor
Propamine a
pyridine-3-carboxamide
Pyridine-3-carboxylic acid amide
S1899_Selleck
SAM001246860
Savacotyl
SGCUT00176
SMR000058212
to_000073
UNII-25X51I8RD4
Vi-nicotyl
Vi-Nicotyl
Vi-noctyl
Vitamin B
Vitamin B (VAN)
Vitamin b 3
Vitamin B 3
Vitamin b3
Vitamin H1
vitamin PP
Vitamin PP
Witamina PP
WLN: T6NJ CVZ
ZINC00005878
β-pyridinecarboxamide
|
|
| 6 |
|
Folic Acid |
Approved, Nutraceutical, Vet_approved |
Phase 3,Phase 2 |
|
59-30-3 |
6037
|
|
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
|
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
| 7 |
|
Niacin |
Approved, Investigational, Nutraceutical |
Phase 3,Phase 2 |
|
59-67-6 |
938
|
|
Synonyms:
3 Pyridinecarboxylic acid
3-Carboxylpyridine
3-carboxypyridine
3-Carboxypyridine
3-Pyridinecarboxylate
3-Pyridinecarboxylic acid
3-Pyridylcarboxylate
3-Pyridylcarboxylic acid
Acide nicotinique
Acide Nicotinique
acido Nicotinico
Acido nicotinico
Acidum nicotinicum
Acidum Nicotinicum
Akotin
Aluminum salt, niacin
Anti-pellagra vitamin
Apelagrin
beta-Pyridinecarboxylate
beta-Pyridinecarboxylic acid
b-Pyridinecarboxylate
b-Pyridinecarboxylic acid
Daskil
Efacin
Enduracin
Hydrochloride, niacin
Induracin
Linic
Lithium nicotinate
m-Pyridinecarboxylate
m-Pyridinecarboxylic acid
M-Pyridinecarboxylic Acid
Niac
Niacin
Niacin aluminum salt
Niacin ammonium salt
Niacin calcium salt
Niacin cobalt (2+) salt
Niacin copper (2+) salt
Niacin hydrochloride
Niacin iron (2+) salt
Niacin lithium salt
Niacin lithium salt, hemihydrate
Niacin magnesium salt
Niacin manganese (2+) salt
Niacin potassium salt
Niacin sodium salt
Niacin tartrate
|
Niacin tosylate
Niacin zinc salt
Niacina
Niacine
Niacor
Nicacid
Nicamin
Nicangin
nico 400
nico-400
Nico400
Nicobid
Nicocap
Nicodelmine
Nicolar
Niconacid
Nicosan 3
nico-Span
Nicotinate
Nicotinate, lithium
Nicotinic Acid
Nicotinipca
Nicyl
Nikotinsaeure
Nyclin
P.P. factor
Pellagra preventive factor
Pellagrin
Pelonin
Potassium salt, niacin
PP Factor
Pyridine-b-carboxylate
Pyridine-b-carboxylic acid
Pyridine-beta-carboxylate
Pyridine-beta-carboxylic acid
Pyridine-β-carboxylate
pyridine-β-carboxylic acid
Pyridine-β-carboxylic acid
slo-Niacin
Sodium salt, niacin
Tartrate, niacin
Tosylate, niacin
Vitamin b3
Vitamin B3
Wampocap
β-pyridinecarboxylate
β-pyridinecarboxylic acid
|
|
| 8 |
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 9 |
|
Hormone Antagonists |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 10 |
|
Hormones |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 11 |
|
Vitamin B Complex |
|
Phase 3,Phase 2 |
|
|
|
| 12 |
|
Trace Elements |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 13 |
|
Vitamins |
|
Phase 3,Phase 2,Not Applicable |
|
|
|
| 14 |
|
Micronutrients |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 15 |
|
Vitamin B9 |
|
Phase 3,Phase 2 |
|
|
|
| 16 |
|
Folate |
|
Phase 3,Phase 2 |
|
|
|
| 17 |
|
cadexomer iodine |
|
Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 18 |
|
Anti-Infective Agents |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 19 |
|
Anti-Infective Agents, Local |
|
Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 20 |
|
Nicotinic Acids |
|
Phase 3,Phase 2 |
|
|
|
| 21 |
|
Vitamin B3 |
|
Phase 3,Phase 2 |
|
|
|
| 22 |
|
Rosiglitazone |
Approved, Investigational |
Phase 2 |
|
122320-73-4 |
77999
|
|
Synonyms:
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
[3H]rosiglitazone
122320-73-4
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-(Methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
AC1L2U9N
AC-3459
Avandia
BRD-A97437073-001-02-3
BRD-A97437073-001-03-1
Brl 49653
Brl-49653
BRL49653
BRL-49653
BSPBio_002693
C18H19N3O3S
CID77999
D08491
DB00412
Gaudil
Gaudil (TN)
glaxo Wellcome brand OF rosiglitazone maleate
GlaxoSmithKline brand OF rosiglitazone maleate
HMS1922J11
HMS2094O13
HSDB 7555
I06-0141
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
KBio2_002183
KBio2_004751
KBio2_007319
|
KBio3_001913
KBioGR_001609
KBioSS_002183
LS-151340
MolPort-002-508-212
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
RGZ
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazon
rosiglitazona
Rosiglitazona
rosiglitazone
Rosiglitazone
rosiglitazone (Avandia)
Rosiglitazone (INN)
Rosiglitazone [INN:BAN]
Rosiglitazone maleate
rosiglitazonum
Rosiglitazonum
Rosiglizole
RSG
S00306
SmithKline beecham brand OF rosiglitazone maleate
SPBio_001142
Spectrum_001703
SPECTRUM1504263
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
STOCK6S-23924
TDZ 01
UNII-05V02F2KDG
|
|
| 23 |
|
Somatostatin |
Approved, Investigational |
Phase 2 |
|
51110-01-1, 38916-34-6 |
53481605
|
|
Synonyms:
Growth hormone-inhibiting hormone (ghih)
Somatostatina
Somatostatine
Somatostatinum
|
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
Synthetic growth hormone release-inhibiting hormone
Synthetic somatostatin-14
|
|
| 24 |
|
Sunitinib |
Approved, Investigational |
Phase 2 |
|
557795-19-4, 341031-54-7 |
5329102
|
|
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
5-(5-fluoro-2-oxo-1,2-Dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
|
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU010398
SU-010398
Su-011248
SU011248
SU011248 L-malate salt
SU-011248 L-malate salt
SU11248
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
Sunitanib
sunitinib
Sunitinib
Sunitinib (free base)
Sunitinib (INN)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
sunitinibum
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
|
|
| 25 |
|
Celecoxib |
Approved, Investigational |
Phase 2 |
|
169590-42-5 |
2662
|
|
Synonyms:
169590-42-5
184007-95-2
1oq5
4-(5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1Hpyrazol-1-yl] benzenesulfonamide
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENESULFONAMIDE
4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide
AC1L1E6K
AC-4228
AI-525
Benzenesulfonamide,4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)
BIDD:GT0408
BRD-K02637541-001-02-4
BSPBio_003596
C07589
C105934
C17H14F3N3O2S
CCRIS 8679
CEL
Celebra
Celebrex
Celebrex (TN)
Celebrex, Celebra, Celecoxib
Celecox
Celecoxi
celecoxib
Celecoxib
Célécoxib
Celecoxib (JAN/USAN/INN)
Celecoxib (SC-58635)
Celecoxib [Old RN]
Celecoxib [USAN]
Celecoxibum
Celocoxib
CEP-33222
CHEBI:41423
CHEMBL118
CID2662
cMAP_000027
CPD000550473
D00567
DB00482
DivK1c_000893
Eurocox
FT-0080064
HMS1922G14
HMS2089L18
HMS2093I07
HMS502M15
HSDB 7038
I01-1033
IDI1_000893
KBio1_000893
|
KBio2_000912
KBio2_002351
KBio2_003480
KBio2_004919
KBio2_006048
KBio2_007487
KBio3_002830
KBio3_003037
KBioGR_000723
KBioGR_002351
KBioSS_000912
KBioSS_002354
LS-31667
Medicoxib
MLS001165684
MLS001195656
MLS001304708
MolPort-002-885-815
NCGC00091455-01
NCGC00091455-02
NCGC00091455-03
NCGC00091455-04
NCI60_041049
NINDS_000893
NSC719627
Onsenal
p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulphonamide
Pfizer brand of celecoxib
S1261_Selleck
SAM002589995
SC 58635
SC-58553, SC-58635
SC58635
SC-58635
SMR000550473
Solexa
SPBio_001512
Spectrum_000432
SPECTRUM1503678
Spectrum2_001576
Spectrum3_001996
Spectrum4_000182
Spectrum5_001324
TL8001323
TPI-336
UNM-0000305813
Xilebao
YM 177
YM177
YM-177
ZINC02570895
|
|
| 26 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953
|
|
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
Capecitabin
capecitabina
Capecitabina
capecitabine
CAPECITABINE
Capécitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
capecitabinum
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
CHEBI:31348
CHEMBL1773
CID60953
D01223
|
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
R340
R-340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
|
|
| 27 |
|
Panobinostat |
Approved, Investigational |
Phase 2 |
|
404950-80-7 |
6918837
|
|
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
Faridak
FT-0083488
LBH 589
|
LBH589
LBH-589
LBH-589B
MolPort-005-933-338
nchembio.313-comp11
NVP-LBH589
NVP-LBH-589
panobinostat
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
|
|
| 28 |
|
Lithium carbonate |
Approved |
Phase 2 |
|
554-13-2 |
|
|
Synonyms:
Carbonic acid, dilithium salt
Dilithium carbonate
|
Lithii carbonas
Lithonate
|
|
| 29 |
|
Valproic Acid |
Approved, Investigational |
Phase 2 |
|
99-66-1 |
3121
|
|
Synonyms:
(N-C3H7)2chcooh
(S)-2-Propyl-4-pentanoate
(S)-2-Propyl-4-pentanoic acid
2 PP (base)
2 Propylpentanoic acid
2-N-Propyl-N-valerate
2-n-propyl-n-valeric acid
2-n-Propyl-n-valeric acid
2-N-Propyl-N-valeric acid
2-Propylpentanoate
2-PROPYL-pentanoate
2-propyl-pentanoic acid
2-Propylpentanoic acid
2-Propylpentanoic Acid
2-PROPYL-pentanoIC ACID
2-Propylvalerate
2-propylvaleric acid
2-Propylvaleric acid
2-Propylvaleric Acid
4-Heptanecarboxylate
4-heptanecarboxylic acid
4-Heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
Abbott 44090
AC1L1F7T
AC1Q2ULA
Acetate, dipropyl
Acid, propylisopropylacetic
Acid, valproic
Acide valproique
acide valproïque
Acide valproique [INN-French]
acido Valproico
Acido valproico
ácido valproico
Acido valproico [INN-Spanish]
acidum valproicum
Acidum valproicum
Acidum valproicum [INN-Latin]
AI3-10500
Alti-valproic
Alti-Valproic
apo-Divalproex
apo-Valproic
apo-Valproic syrup
Avugane
Baceca
BIDD:GT0858
BRN 1750447
C07185
Calcium valproate
Calcium, valproate
CHEBI:39867
CHEMBL109
CID3121
Convulex
Convulsofin
CPD000499581
D00399
DB00313
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetate
di-n-propylacetic acid
Di-n-propylacetic acid
Di-N-propylacetic acid
Di-n-propylessigsaeure
Di-N-propylessigsaeure
Di-n-propylessigsaure
Di-N-propylessigsaure
Di-n-propylessigsäure
Di-n-propylessigsaure [German]
Dipropyl acetate
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
Divalproex
Divalproex sodium
DivK1c_000273
DOM-divalproex
Dom-valproate
Dom-Valproic
DOM-valproic
Dom-valproic acid
DOM-valproic acid e.c.
Dom-valproic acid syrup
DPA
EINECS 202-777-3
Epiject i.v.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
|
KBio2_004845
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
Magnesium valproate
Med valproic
Med Valproic
MLS001076682
MLS001335927
MLS001335928
MLS002415770
MolPort-001-791-895
Mylproin
Myproate
Myproic acid
Myproic Acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
nchembio.79-comp4
nchembio815-comp21
n-Dipropylacetic acid
N-Dipropylacetic acid
n-DPA
N-DPA
NINDS_000273
novo-Divalproex
novo-Valproic
Novo-Valproic
novo-Valproic - ecc
novo-Valproic soft gel cap
NSC 93819
NSC93819
Nu-valproic
Nu-Valproic
P0823
P6273_SIGMA
PEAC
Penta-valproic
Penta-Valproic
PHL-Valproate
PHL-Valproic acid
PHL-Valproic acid e.c.
PMS-Divalproex
PMS-Valproate
PMS-Valproic acid
PMS-Valproic Acid
PMS-Valproic acid e.c.
Propylisopropylacetic acid
Propylvaleric acid
ratio-Valproic - ecc
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
Sandoz valproic
Savicol
SBB065764
Semisodium valproate
Semisodium Valproate
SMR000499581
Sodium hydrogen divalproate
Sodium valproate
Sodium, divalproex
Sodium, valproate
SPBio_000912
Spectrum_000521
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Sprinkle
Stavzor
UNII-614OI1Z5WI
Valcote
Valparin
valproate
Valproate
Valproate calcium
Valproate semisodique [French]
Valproate semisodium
Valproate sodium
Valproate, calcium
Valproate, magnesium
Valproate, semisodium
Valproate, sodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
valproic acid
Valproic acid
VALPROIC ACID
Valproic acid (USP)
Valproic acid [USAN:INN:BAN]
Valproic acid usp
Valproic acid USP
Valproic acid USP24
Valproic acid, sodium salt (2:1)
Valproic Acid, Sodium Salt (2:1)
Valproinsaeure
Valproinsäure
VPA
Vupral
WLN: QVY3 & 3
|
|
| 30 |
|
Bortezomib |
Approved, Investigational |
Phase 2 |
|
179324-69-7 |
387447
93860
|
|
Synonyms:
[(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
179324-69-7
341, PS
AC1L8TUW
bortezomib
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP 341
LDP341
LDP-341
|
LPD 341
LPD-341
MLN341
MolPort-003-845-298
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
NCI60_029010
NSC681239
NSC-681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
|
|
| 31 |
|
Vemurafenib |
Approved |
Phase 2,Not Applicable |
|
918504-65-1 |
23252090
42611257
|
|
Synonyms:
BRAF(V600E) Kinase Inhibitor RO5185426
PLX4032
PLX-4032
R05185426
|
RG7204
RO5185426
vemurafenib
Zelboraf
|
|
| 32 |
|
Metformin |
Approved |
Phase 2,Not Applicable |
|
657-24-9 |
14219
4091
|
|
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
cMAP_000016
D04966
DB00331
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMGG
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
Haurymelin
HMS2089D19
HSCI1_000295
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
|
KBioSS_002312
LA-6023
LS-43899
Melbin
metformin
Metformin
Metformin (USAN/INN)
Metformin [USAN:INN:BAN]
Metformin HCL
metformin hydrochloride
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
Sandoz Metformin
Siofor
SPBio_001928
STK011633
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
|
|
| 33 |
|
Dabrafenib |
Approved, Investigational |
Phase 2,Not Applicable |
|
1195765-45-7 |
44462760
44516822
|
|
Synonyms:
BRAF inhibitor GSK2118436
dabrafenib
Dabrafenib
|
|
|
| 34 |
|
Trametinib |
Approved |
Phase 2,Phase 1 |
|
871700-17-3 |
11707110
|
|
Synonyms:
GSK1120212
JTP-74057
MEK Inhibitor GSK1120212
Mekinist
|
trametinib
Trametinib
Tramétinib
Trametinibum
|
|
| 35 |
|
Cisplatin |
Approved |
Phase 2,Phase 1 |
|
15663-27-1 |
2767
441203
84093
|
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
| 36 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703
|
|
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
doxo Cell
doxo-Cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin HCl
|
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
| 37 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314
|
|
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-epi-Paclitaxel
7-Epipaclitaxel
7-Epi-paclitaxel
7-epi-Taxol
7-Epitaxol
7-Epi-taxol
AB00513812
ABI 007
abi-007
ABI007
ABI-007
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
AC1L1IOG
AC1L1VJI
AC1L9AVF
AC-675
ACon1_002231
albumin-bound paclitaxel
Ambotz33069-62-4
ANX-513
Anzatax
Asotax
BIDD:PXR0046
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
Bris taxol
Bristaxol
BSPBio_000290
BSPBio_001152
BSPBio_002614
C07394
C466458
C47H51NO14
Capxol
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
cMAP_000068
CPD-8718
D00491
DB01229
DHP-107
DHP-208
DivK1c_000441
DRG-0190
DTS-301
Ebetaxel
EmPAC
Epitaxol
EU-0101201
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
|
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LipoPac
LMPR0104390001
Lopac0_001201
LS-31070
MBT 0206
MEGxp0_001940
Micellar Paclitaxel
Mitotax
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
MPI-5018
nab-paclitaxel
Nanotaxel
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
NCI60_000601
Neuro_000060
NINDS_000441
NK 105
Nova-12005
NP-010981
NSC 125973
NSC125973
NSC-125973
NSC358882
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
paclitaxel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S1150_Selleck
S-8184 Paclitaxel Injectable Emulsion
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
Spectrum_001536
SPECTRUM1503908
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
ST50306996
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TaxAlbin
Taxol
TAXOL
TAXOL (TN)
Taxol a
Taxol A
Taxol Konzentrat
TAXOL, 10-EPI,
Taxol, bris
Taxol.RTM. (Registered Trademark)
TXL
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
weekly paclitaxel
Xorane
Yewtaxan
|
|
| 38 |
|
Bevacizumab |
Approved, Investigational |
Phase 2 |
|
216974-75-3 |
|
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
| 39 |
|
Atezolizumab |
Approved, Investigational |
Phase 2,Phase 1 |
|
1380723-44-3 |
|
|
Synonyms:
|
| 40 |
|
Benzocaine |
Approved, Investigational |
Phase 2 |
|
94-09-7, 1994-09-7 |
2337
|
|
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl Aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
|
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-Aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-Aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
p-Ethoxycarboxylic Aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
| 41 |
|
tannic acid |
Approved |
Phase 2 |
|
|
|
| 42 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
6442177
|
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
|
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
| 43 |
|
Sirolimus |
Approved, Investigational |
Phase 2 |
|
53123-88-9 |
46835353
6436030
5284616
|
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
| 44 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 2 |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 45 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
6055-19-2, 50-18-0 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 46 |
|
Radium Ra 223 dichloride |
Approved, Investigational |
Phase 2 |
|
444811-40-9 |
|
|
Synonyms:
RADIUM CHLORIDE RA-223
Radium Ra-223 dichloride
|
Radium-223 chloride
Radium-223 dichloride
|
|
| 47 |
|
Pembrolizumab |
Approved |
Phase 2 |
|
1374853-91-4 |
|
|
Synonyms:
|
| 48 |
|
Salmon Calcitonin |
Approved, Investigational |
Phase 2 |
|
47931-85-1 |
16129616
|
|
Synonyms:
135506-95-5
47931-85-1
Astronin
Biocalcin
Bionocalcin
C028815
C06865
C145H239N43O48S2
Cadens
Calciben
Calcihexal
Calcimar
Calcimar (TN)
Calcimonta
Calcinil
Calcioton
Calcitonin (Salmon Synthetic)
Calcitonin (salmon)
Calcitonin [USAN:INN:BAN:JAN]
Calcitonin salmon
Calcitonin Salmon
Calcitonin salmon (synthesis)
Calcitonin salmon (synthesis) (JAN)
Calcitonin salmon (USAN/INN)
Calcitonin salmon recombinant
Calcitonin vom lachs
Calcitonin, salmar
Calcitonin, salmon
CALCITONIN, SALMON
Calcitonin, salmon, for bioassay
Calcitonin,salmon
Calcitonina
Calcitonine de saumon
Calcitonin-salmon
Calcitoran
Calco
Calogen
Calsynar
Calsynar Lyo L
Caltine
Casalm
Catonin
Cibacalcin
Cibacalcine
Citonina
D00249
|
EINECS 256-342-8
Eptacalcin
Forcaltonin
Fortical
Fortical (TN)
Ipocalcin
Isi-calcin
Kalsimin
Karil
LS-48624
Miacalcic
Miacalcin
Miacalcin (TN)
Miracalcic
Oseototal
Osseocalcina
Osteobion
Osteovis
Ostosalm
Ostostabil
Porostenina
Prontocalcin
Quosten
recombinant salmon calcitonin
Recombinant salmon calcitonin
Riostin
Rulicalcin
Salcat
Salcatonin
Salcatyn
Salmocalcin
Salmofar
Salmon calcitonin
salmon calcitonin (1-32)
Salmon calcitonin I
Salmon calcitonin-(I-32)
Sical
Stalcin
Staporos
Steocin
synthetic salmon calcitonin
Thyrocalcitonin (salmon)
Tonocalcin
TZ-CT
Ucecal
UNII-7SFC6U2VI5
|
|
| 49 |
|
Irinotecan |
Approved, Investigational |
Phase 1, Phase 2 |
|
100286-90-6, 97682-44-5 |
60838
|
|
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
7-Ethyl-10-hydroxycamptothecin
97682-44-5
AC1L1U0Z
AC1Q6PGI
AC-7469
Bio-0054
Biotecan
Biotecan (TN)
BRD-K08547377-003-02-4
BSPBio_002346
C16641
C33H38N4O6
Campothecin-11
Campto
Camptosar
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
CHEBI:105985
CHEMBL481
CID60838
CP0
CPT 11
CPT-11
D08086
DB00762
|
FT-0083650
HSDB 7607
Irinophore C
irinotecan
Irinotecan (INN)
Irinotecan [INN:BAN]
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan Hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan Hydrochloride Trihydrate
IRINOTECAN HYDROCHLORIDE Trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
LS-44589
NCI60_005051
NK012 Compound
NSC728073
S1198_Selleck
sn 38
sn-38
sn38 CPD
TL8006026
UNII-7673326042
|
|
| 50 |
|
Oxaliplatin |
Approved, Investigational |
Phase 1, Phase 2,Phase 2 |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
Interventional clinical trials:
(show top 50)
(show all 130)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer |
Recruiting |
NCT03573960
|
Phase 4 |
Lenvatinib |
| 2 |
Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy |
Recruiting |
NCT02946918
|
Phase 4 |
Levothyroxine |
| 3 |
Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients |
Unknown status |
NCT00435851
|
Phase 3 |
Thyrogen, thyroid hormone withdrawal, iode 131 |
| 4 |
Multicenter Study Differentiated Thyroid Carcinoma |
Completed |
NCT00144079
|
Phase 3 |
|
| 5 |
Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer |
Completed |
NCT00984282
|
Phase 3 |
Sorafenib (Nexavar, BAY43-9006);Placebo |
| 6 |
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. |
Completed |
NCT00295763
|
Phase 3 |
Thyrogen (thyrotropin alfa for injection) |
| 7 |
The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer |
Completed |
NCT00794053
|
Phase 3 |
|
| 8 |
Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration |
Completed |
NCT00196729
|
Phase 3 |
Thyrogen + Radioiodine (131I) |
| 9 |
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032) |
Recruiting |
NCT02586337
|
Phase 2, Phase 3 |
Anlotinib;Placebo |
| 10 |
Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer |
Recruiting |
NCT03048877
|
Phase 3 |
Apatinib Oral Tablet;Placebo Oral Tablet |
| 11 |
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China |
Recruiting |
NCT02966093
|
Phase 3 |
Lenvatinib;Placebo |
| 12 |
Donafenib in 131I-Refractory Differentiated Thyroid Cancer |
Recruiting |
NCT03602495
|
Phase 3 |
Donafenib;Placebo |
| 13 |
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-targeted Therapy |
Recruiting |
NCT03690388
|
Phase 3 |
Cabozantinib;Placebo |
| 14 |
Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? |
Recruiting |
NCT01837745
|
Phase 3 |
rhTSH stimulation;I131 |
| 15 |
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients |
Recruiting |
NCT01398085
|
Phase 2, Phase 3 |
|
| 16 |
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer |
Active, not recruiting |
NCT01843062
|
Phase 3 |
Selumetinib;Placebo;Radioactive Iodine Therapy |
| 17 |
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer |
Active, not recruiting |
NCT01876784
|
Phase 3 |
Vandetanib (SAR390530);Placebo |
| 18 |
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer |
Active, not recruiting |
NCT02418247
|
Phase 2, Phase 3 |
I131;I123 |
| 19 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) |
Active, not recruiting |
NCT01321554
|
Phase 3 |
Lenvatinib;Placebo;Lenvatinib |
| 20 |
High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid Cancer |
Active, not recruiting |
NCT00415233
|
Phase 3 |
|
| 21 |
ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer |
Not yet recruiting |
NCT03570021
|
Phase 3 |
|
| 22 |
Study of Apatinib in Patients With Differentiated Thyroid Cancer |
Unknown status |
NCT02731352
|
Phase 2 |
Apatinib |
| 23 |
A Multicenter Phase II Pilot Open Label |
Unknown status |
NCT01830504
|
Phase 2 |
BKM120 |
| 24 |
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer |
Unknown status |
NCT00098852
|
Phase 2 |
rosiglitazone maleate |
| 25 |
Redifferentiation Therapy Using Alpha Lipoic Acid in Thyroid Cancer |
Unknown status |
NCT01396733
|
Phase 2 |
alpha-lipoic acids |
| 26 |
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms |
Unknown status |
NCT01237457
|
Phase 2 |
177Lu-DOTATATE |
| 27 |
Effect of Carum Carvi on Thyroid Hormones and TSH Level |
Unknown status |
NCT01471288
|
Phase 1, Phase 2 |
Carum Cravi;Placebo |
| 28 |
Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma |
Completed |
NCT02515084
|
Phase 2 |
|
| 29 |
Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer |
Completed |
NCT00061906
|
Phase 2 |
celecoxib |
| 30 |
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer |
Completed |
NCT00668811
|
Phase 2 |
SU011248, Sutent |
| 31 |
Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology |
Completed |
NCT00784303
|
Phase 2 |
E7080 |
| 32 |
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer |
Completed |
NCT00124527
|
Phase 2 |
Irofulven + capecitabine |
| 33 |
Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer. |
Completed |
NCT00279721
|
Phase 2 |
|
| 34 |
Study of External Beam Radiotherapy to Thyroid Carcinoma |
Completed |
NCT01173289
|
Phase 2 |
|
| 35 |
Trial of LBH589 in Metastatic Thyroid Cancer |
Completed |
NCT01013597
|
Phase 2 |
LBH589 |
| 36 |
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer |
Completed |
NCT00118248
|
Phase 2 |
tanespimycin |
| 37 |
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer |
Completed |
NCT00251316
|
Phase 2 |
Lithium Carbonate;Placebo |
| 38 |
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer |
Completed |
NCT01811212
|
Phase 2 |
Cabozantinib S-malate |
| 39 |
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer |
Completed |
NCT01229865
|
Phase 2 |
VB-111 |
| 40 |
Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer |
Completed |
NCT00519896
|
Phase 2 |
sunitinib malate |
| 41 |
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma |
Completed |
NCT00887107
|
Phase 2 |
Sorafenib (nexavar) |
| 42 |
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer |
Completed |
NCT00654238
|
Phase 2 |
sorafenib |
| 43 |
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer |
Completed |
NCT00181168
|
Phase 2 |
Euthyroid Group |
| 44 |
A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin |
Completed |
NCT01182285
|
Phase 2 |
Valproic Acid;Liothyronine Sodium |
| 45 |
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy |
Completed |
NCT00104871
|
Phase 2 |
Bortezomib |
| 46 |
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer |
Completed |
NCT00121628
|
Phase 2 |
AMG 706 |
| 47 |
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma |
Recruiting |
NCT03167385
|
Phase 2 |
Apatinib Mesylate |
| 48 |
PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma |
Recruiting |
NCT03387943
|
Phase 2 |
PLD;Cisplatin |
| 49 |
A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting |
Recruiting |
NCT02041260
|
Phase 2 |
Cabozantinib |
| 50 |
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas |
Recruiting |
NCT03181100
|
Phase 2 |
Nab-paclitaxel - INDUCTION COHORT;Paclitaxel - INDUCTION COHORT;Vemurafenib - COHORT 1;Cobimetinib - COHORT 1;Atezolizumab - COHORT 1;Bevacizumab - COHORT 3;Nab-paclitaxel - COHORT 4;Paclitaxel - COHORT 4;Cobimetinib - COHORT 2;Atezolizumab - COHORT 2;Atezolizumab - COHORT 3;Atezolizumab - COHORT 4 |
|
